Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8603898 | 0.92 | — | — | |
| SCHEMBL8572734 | 0.87 | ALDH1A1 (0.58) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1538351 | 0.86 | ALDH1A1 (0.35) | ALDH1A1 | |
| Ethylene Glycol SCHEMBL907984 | 0.82 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5576032 | 0.80 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL10446645 | 0.80 | TSHR (0.39) | ALDH1A1 | |
| SCHEMBL2576138 | 0.75 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL10446643 | 0.75 | TSHR (0.38) | ALDH1A1 | |
| SCHEMBL1395028 | 0.74 | — | — | |
| SCHEMBL19376407 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391060-B2 | Particulate delivery systems | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2019-08-27 | — | — | US | claimed |
| US-20190000763-A1 | PARTICULATE DELIVERY SYSTEMS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2019-01-03 | — | — | US | claimed |
| US-20070009441-A1 | Biodegradable nanoparticles | MOLECULAR THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | US | claimed |
| WO-2006010083-A2 | BIODEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005089106-A2 | DEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-08 | — | — | US | claimed |
| US-10391060-B2 | Particulate delivery systems | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2019-08-27 | — | — | US | disclosed |
| US-20190000763-A1 | PARTICULATE DELIVERY SYSTEMS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2019-01-03 | — | — | US | disclosed |
| WO-2017021983-A1 | PARTICULATE DELIVERY SYSTEMS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-02-09 | — | — | WO | disclosed |
| US-20070009441-A1 | Biodegradable nanoparticles | MOLECULAR THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2006010083-A2 | BIODEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005089106-A2 | DEGRADABLE NANOPARTICLES | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | MOLECULAR THERAPEUTICS, INC. (US) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070009441-A1 | Biodegradable nanoparticles | CD47, CD63, ECPAS | ALDH1A1 551/4885HMGCR 1823/4885CHRM1 4156/4885 |
| US-20050196343-A1 | Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body | ECPAS, ACTB, SERPINB10 | ALDH1A1 1098/4885HMGCR 1575/4885CHRM1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.